Declining healthcare spending combined with increased
pressure on the HC system budget is creating an incentive for
patients to consent to new treatments, and fostering a positive
environment for the development of the CT sector. There are
a multitude of factors that influence companies’ decisions to
open clinical operations in Russia for all types of clinical trials.
In this article, Jane Gelfand, Managing Director and Kristina
Dutchak, Programme Director at Adam Smith Conferences,
analyse the key factors that are shaping the Russian and CIS
market for clinical trials, and discuss the regulatory initiatives
that are coming into force to facilitate its further development.